Anthem Biosciences Limited (BOM:544449)

Market Cap	365.89B
Revenue (ttm)	20.77B
Net Income (ttm)	5.16B
Shares Out	n/a
EPS (ttm)	9.21
PE Ratio	70.89
Forward PE	60.74
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,798
Average Volume	127,740
Open	643.95
Previous Close	639.60
Day's Range	637.65 - 653.60
52-Week Range	620.05 - 873.25
Beta	n/a
RSI	44.09
Earnings Date	Nov 8, 2025

About Anthem Biosciences

Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients. The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the concept stage; preclinical development; and manufacturing development batches of molecules used for clinical Phase I, II, and III trials up to commercial...

• Industry: Commercial Physical and Biological Research
• Founded: 2006
• Employees: 1,825
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 544449

Financial Performance

In 2024, Anthem Biosciences's revenue was 18.50 billion, an increase of 30.29% compared to the previous year's 14.20 billion. Earnings were 4.51 billion, an increase of 22.86%.